The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs
Open accessAbstract
Despite evidence of chronic inflammation in myelodysplastic syndrome (MDS) and cell-intrinsic dysregulation of Toll-like receptor (TLR) signaling in MDS hematopoietic stem and progenitor cells (HSPCs), the mechanisms responsible for the competitive advantage of MDS HSPCs in an inflammatory milieu over normal HSPCs remain poorly defined. Here, we found that chronic inflammation was a determinant for the competitive advantage of MDS HSPCs and for disease progression. The cell-intrinsic response of MDS HSPCs, which involves signaling through the noncanonical NF-κB pathway, protected these cells from chronic inflammation as compared to normal HSPCs. In response to inflammation, MDS HSPCs switched from canonical to noncanonical NF-κB signaling, a process that was dependent on TLR-TRAF6-mediated activation of A20. The competitive advantage of TLR-TRAF6-primed HSPCs could be restored by deletion of A20 or inhibition of the noncanonical NF-κB pathway. These findings uncover the mechanistic basis for the clonal dominance of MDS HSPCs and indicate that interfering with noncanonical NF-κB signaling could prevent MDS progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and exhibit a toll-like receptor–TNF receptor associated factor 6A (TLR-TRAF6A) and noncanonical NF-κB–dependent competitive advantage during low-grade inflammation.17”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The non-canonical NF-κB pathway in immunity and inflammation
Sun, S. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.52 · Cited by 1,959
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling
Wertz, I. E., O’Rourke, K. M., Zhou, H., Eby, M. T., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R. T., Boone, D. L., et al. (2004) · Nature · doi:10.1038/nature02794 · Cited by 1,889
Self-citationHaeussler, M., Schönig, K., Eckert, H., Eschstruth, A., Mianné, J., Renaud, J.-B., Schneider-Maunoury, S., Shkumatava, A., Teboul, L., Kent, J., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1012-2 · Cited by 1,756
Greenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,625
Self-citationFailure to Regulate TNF-Induced NF-κB and Cell Death Responses in A20-Deficient Mice
Lee, E. G., Boone, D. L., Chai, S., Libby, S. L., Chien, M., Lodolce, J. P., & Ma, A. (2000) · Science · doi:10.1126/science.289.5488.2350 · Cited by 1,409
Self-citationTet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. (2015) · Nature · doi:10.1038/nature15252 · Cited by 807
Sato, S., Sugiyama, M., Yamamoto, M., Watanabe, Y., Kawai, T., Takeda, K., & Akira, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4304 · Cited by 730
Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype
Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., Hirst, M., Hogge, D., Marra, M., Wells, R. A., et al. (2010) · Nature Medicine · doi:10.1038/nm.2054 · Cited by 577
Self-citationInflammation: a key regulator of hematopoietic stem cell fate in health and disease
Pietras, E. M. (2017) · Blood · doi:10.1182/blood-2017-06-780882 · Cited by 417
Cited by
Sorted by citations
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 463
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata‐Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 319
Caiado, F., Pietras, E. M., & Manz, M. G. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201541 · Cited by 289
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189
Self-citationAging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling
Caiado, F., Kovtonyuk, L. V., Gonullu, N. G., Fullin, J., Boettcher, S., & Manz, M. G. (2023) · Blood · doi:10.1182/blood.2022016835 · Cited by 161
TET Enzymes in the Immune System: From DNA Demethylation to Immunotherapy, Inflammation, and Cancer
López-Moyado, I. F., Ko, M., Hogan, P. G., & Rao, A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-080223-044610 · Cited by 121
IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
Bennett, J., & Starczynowski, D. T. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000693 · Cited by 100
Self-citationClonal hematopoiesis and associated diseases: A review of recent findings
Asada, S., & Kitamura, T. (2021) · Cancer Science · doi:10.1111/cas.15094 · Cited by 104
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 103
Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia
Chlon, T. M., Stepanchick, E., Hershberger, C. E., Daniels, N. J., Hueneman, K. M., Davis, A. K., Choi, K., Zheng, Y., Gurnari, C., Haferlach, T., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.08.004 · Cited by 94
Self-citationPU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress
Chavez, J. S., Rabe, J. L., Loeffler, D., Higa, K. C., Hernandez, G., Mills, T. S., Ahmed, N., Gessner, R. L., Ke, Z., Idler, B. M., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201169 · Cited by 91
“Aberrant signaling via IL-1 and the downstream IL-1 receptor associated kinase/TNF receptor associated factor pathway shared by IL-1R and TLRs has been implicated as a driver of survival and/or expansion of MDS and myeloid leukemia stem cells (Ågerstam et al., 2016; Askmyr et al., 2013; Barreyro et al., 2012; Carey et…”
BackgroundLefkopoulos, S., Polyzou, A., Derecka, M., Bergo, V., Clapes, T., Cauchy, P., Jerez‐Longres, C., Onishi‐Seebacher, M., Yin, N., Calderón, N. M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.007 · Cited by 85
Wang, T., Pine, A. R., Kotini, A. G., Yuan, H., Zamparo, L., Starczynowski, D. T., Leslie, C. S., & Papapetrou, E. P. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.011 · Cited by 77
Self-citationChavakis, T., Wielockx, B., & Hajishengallis, G. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-052521-013627 · Cited by 75
Muto, T., Guillamot, M., Yeung, J., Fang, J., Bennett, J. R., Nadorp, B., Lasry, A., Zea-Redondo, L., Choi, K., Gong, Y., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2021.12.007 · Cited by 60
Self-citationTET2: A cornerstone in normal and malignant hematopoiesis
Kunimoto, H., & Nakajima, H. (2020) · Cancer Science · doi:10.1111/cas.14688 · Cited by 56
Hand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis
SanMiguel, J. M., Young, K. A., & Trowbridge, J. J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.197 · Cited by 59
Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies
Camacho, V., Kuznetsova, V., & Welner, R. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772408 · Cited by 60
Paracatu, L. C., & Schuettpelz, L. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01236 · Cited by 51
Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1
Agarwal, P., Sampson, A. M., Hueneman, K. M., Choi, K., Jakobsen, N. A., Uible, E. E., Ishikawa, C., Yeung, J., Bolanos, L. C., Zhao, X., et al. (2025) · Nature · doi:10.1038/s41586-025-08938-8 · Cited by 56
Self-citationInflammation and myeloid malignancy: quenching the flame
Stubbins, R. J., Platzbecker, U., & Karsan, A. (2022) · Blood · doi:10.1182/blood.2021015162 · Cited by 46
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
Kouroukli, O., Symeonidis, A. S., Foukas, P. G., Maragkou, M., & Kourea, E. P. (2022) · Cancers · doi:10.3390/cancers14225656 · Cited by 52
Mechanisms involved in hematopoietic stem cell aging
Fujino, T., Asada, S., Goyama, S., & Kitamura, T. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04356-5 · Cited by 49
NF-κB and Human Cancer: What Have We Learned over the Past 35 Years?
Gilmore, T. D. (2021) · Biomedicines · doi:10.3390/biomedicines9080889 · Cited by 47
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia
Barreyro, L., Sampson, A. M., Ishikawa, C., Hueneman, K. M., Choi, K., Pujato, M. A., Chutipongtanate, S., Wyder, M. A., Haffey, W. D., O'Brien, E. J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abb7695 · Cited by 45
Self-citationWu, Q., Zhang, W., Lu, Y., Li, H., Yang, Y., Geng, F., Liu, J., Li, L., Pan, Y., & Li, C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111558 · Cited by 47
de Boer, B., Sheveleva, S., Apelt, K., Vellenga, E., Mulder, A. B., Huls, G. A., & Schuringa, J. J. (2020) · Haematologica · doi:10.3324/haematol.2020.254987 · Cited by 43
McLemore, A. F., Hou, H., Meyer, B. S., Lam, N. B., Ward, G., Aldrich, A. L., Rodrigues, M. A., Vedder, A., Zhang, L., Padron, E., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159430 · Cited by 42
Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy
Kanagal‐Shamanna, R., Beck, D. B., & Calvo, K. R. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-122724 · Cited by 46
Therapeutic targeting of the inflammasome in myeloid malignancies
Chakraborty, S., Shapiro, L. C., de Oliveira, S., Rivera-Peña, B., Verma, A. K., & Shastri, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00547-8 · Cited by 40
Chen, R., Okeyo-Owuor, T., Patel, R. M., Casey, E. B., Cluster, A. S., Yang, W., & Magee, J. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108751 · Cited by 36
Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes
Aoyagi, Y., Hayashi, Y., Harada, Y., Choi, K., Matsunuma, N., Sadato, D., Maemoto, Y., Ito, A., Yanagi, S., Starczynowski, D. T., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0032 · Cited by 35
Self-citationCulver‐Cochran, A. E., Hassan, A., Hueneman, K. M., Choi, K., Ma, A. I., VanCauwenbergh, B., O'Brien, E. J., Wunderlich, M., Perentesis, J. P., & Starczynowski, D. T. (2024) · Nature Communications · doi:10.1038/s41467-024-53629-z · Cited by 37
Self-citationImmuno-Modulation of Hematopoietic Stem and Progenitor Cells in Inflammation
Sezaki, M., Hayashi, Y., Wang, Y., Johansson, A., Umemoto, T., & Takizawa, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585367 · Cited by 38
Wang, Y., Hou, H., Lin, C., Kuo, Y., Yao, C., Hsu, C., Tseng, M., Tsai, C., Peng, Y., Kao, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005141 · Cited by 37
Chen, L., Pronk, E., van Dijk, C., Bian, Y., Feyen, J., van Tienhoven, T. V. D., Yildirim, M., Pisterzi, P., de Jong, M. M. E., Bastidas, A., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0043 · Cited by 37
Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Zavras, P. D., Sinanidis, I., Tsakiroglou, P., & Karantanos, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055018 · Cited by 33
Emergency myelopoiesis in solid cancers
Aliazis, K., Yenyuwadee, S., Phikulsod, P., & Boussiotis, V. A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19656 · Cited by 34
Sato, N., Goyama, S., Chang, Y., Miyawaki, M., Fujino, T., Koide, S., Denda, T., Liu, X., Ueda, K., Yamamoto, K., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00579-w · Cited by 38
TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease
Niederkorn, M., Agarwal, P., & Starczynowski, D. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.08.010 · Cited by 31
Self-citationFate of Hematopoiesis During Aging. What Do We Really Know, and What are its Implications?
Broxmeyer, H. E., Liu, Y., Kapur, R., Orschell, C. M., Aljoufi, A., Ropa, J. P., Trinh, T. L. P., Burns, S. S., & Capitano, M. L. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10065-y · Cited by 30
Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective
Hayashi, Y., Harada, Y., & Harada, H. (2022) · Leukemia · doi:10.1038/s41375-022-01548-7 · Cited by 27
Targeting the Microenvironment in MDS: The Final Frontier
Teodorescu, P., Paşca, S., Dima, D. M., Tomuleasa, C., & Ghiaur, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01044 · Cited by 25
Cell Competition Boosts Clonal Evolution and Hypoxic Selection in Cancer
Madan, E., Peixoto, M. L., Dimitrion, P. M., Eubank, T. D., Yekelchyk, M., Talukdar, S., Fisher, P. B., Mi, Q., Moreno, E., & Gogna, R. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.10.002 · Cited by 26
TNFAIP3 Plays a Role in Aging of the Hematopoietic System
Smith, M. A., Culver‐Cochran, A. E., Adelman, E. R., Rhyasen, G. W., Ma, A. I., Figueroa, M. E., & Starczynowski, D. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.536442 · Cited by 20
Self-citationKong, T., Laranjeira, A. B. A., Letson, C. T., Yu, L. C., Lin, S., Fowles, J. S., Fisher, D. A. C., Ng, S., Yang, W., He, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55643-7 · Cited by 22
Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms
Roussel, X., Garnache‐Ottou, F., & Renosi, F. (2022) · Cancers · doi:10.3390/cancers14143545 · Cited by 21
Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias
Raundhal, M. R., Ghosh, S., Myers, S. A., Cuoco, M. S., Singer, M., Carr, S. A., Waikar, S. S., Bonventre, J. V., Ritz, J., Stone, R. M., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00895-4 · Cited by 20
Chronic TNF in the aging microenvironment exacerbates Tet2 loss-of-function myeloid expansion
Quin, C., DeJong, E. N., McNaughton, A. J. M., Buttigieg, M. M., Basrai, S., Abelson, S., LARCHÉ, M. J., Rauh, M. J., & Bowdish, D. M. E. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011833 · Cited by 20
Laranjeira, A. B. A., Kong, T., Snyder, S. C., Fulbright, M. C., Fisher, D. A. C., Starczynowski, D. T., & Oh, S. T. (2024) · Blood · doi:10.1182/blood.2023022804 · Cited by 18
Self-citationAljoufi, A., Zhang, C., Ropa, J. P., Chang, W., Palam, L. R., Cooper, S. H., Ramdas, B., Capitano, M. L., Broxmeyer, H. E., & Kapur, R. (2022) · Blood · doi:10.1182/blood.2022015499 · Cited by 20
Truncated CSF3 receptors induce pro‐inflammatory responses in severe congenital neutropenia
Olofsen, P. A., Bosch, D. A., de Looper, H. W. J., van Strien, P. M. H., Hoogenboezem, R. M., Roovers, O., van der Velden, V. H. J., Bindels, E. M., de Pater, E., & Touw, I. P. (2022) · British Journal of Haematology · doi:10.1111/bjh.18477 · Cited by 16
The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies
Leśniak, M., Lipniarska, J., Majka, P., Kopyt, W., Lejman, M., & Zawitkowska, J. (2023) · Vaccines · doi:10.3390/vaccines11020277 · Cited by 15
PU.1 is required to restrain myelopoiesis during chronic inflammatory stress
Chavez, J. S., Rabe, J. L., Niño, K. E., Wells, H. H., Gessner, R. L., Mills, T. S., Hernandez, G., & Pietras, E. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1204160 · Cited by 14
“…in response to a wide range of physiological insults, and IL-1 signaling is closely linked to a wide variety of chronic inflammatory diseases, where it plays a critical role in the activation of inflammatory myelopoiesis (Ueda et al., 2009; Dinarello, 2011; Mirantes et al., 2014; Pietras, 2017).”
BackgroundEmerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes
Vallelonga, V., Gandolfi, F., Ficara, F., Porta, M. G. D., & Ghisletti, S. (2023) · Biomedicines · doi:10.3390/biomedicines11102613 · Cited by 15
Barreyro, L., Sampson, A. M., Hueneman, K. M., Choi, K., Christie, S., Ramesh, V., Wyder, M. A., Wang, D., Pujato, M. A., Greis, K. D., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109809 · Cited by 14
Self-citationCui, B., Ai, L., Lei, M., Duan, Y.-J., Tang, C., Zhang, J., Gao, Y., Li, X., Zhu, C., Zhang, Y., et al. (2024) · Blood · doi:10.1182/blood.2024025618 · Cited by 14
Kállai, A., Ungvari, A., Csabán, D., Őrfi, Z., Lehoczki, A., Harasztdombi, J., Yabluchanskiy, A., Benyó, Z., Szappanos, Á., Tarantini, S., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01654-1 · Cited by 14
Gurnari, C., & Visconte, V. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107038 · Cited by 13
Fan, A. C., Nakauchi, Y., Bai, L., Azizi, A., Nuno, K. A., Zhao, F., Köhnke, T., Karigane, D., Hernandez, D. C., Reinisch, A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167053 · Cited by 16
Epigenetic roles in clonal hematopoiesis and aging kidney-related chronic kidney disease
Ogura, Y., & Mimura, I. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1281850 · Cited by 13
The effect of inflammatory factors and their inhibitors on the hematopoietic stem cells fate
Najafi, S., Ghanavat, M., Shahrabi, S., Gatavizadeh, Z., & Saki, N. (2021) · Cell Biology International · doi:10.1002/cbin.11545 · Cited by 13
Restricting genomic actions of innate immune mediators on fetal hematopoietic progenitor cells
Tran, V. L., Liu, P., Katsumura, K. R., Kim, E., Schoff, B. M., Johnson, K. D., & Bresnick, E. H. (2023) · iScience · doi:10.1016/j.isci.2023.106297 · Cited by 13
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia
Deschamps, P., Wacheux, M., Gosseye, A., Morabito, M., Pagès, A., Lyne, A.-M., Alfaro, A., Rameau, P., Imanci, A., Chelbi, R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180738 · Cited by 14
Cui, X., Dong, Y., Zhan, Q., Huang, Y., Zhu, Q., Zhang, Z., Yang, G., Wang, L., Shen, S., Zhao, J., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2754-9 · Cited by 14
Stalmann, U., Ticconi, F., Snoeren, I., Li, R., Gleitz, H. F. E., Cowley, G. S., McConkey, M. E., Wong, A. B., Schmitz, S., Fuchs, S. N. R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006061 · Cited by 11
Paracatu, L. C., Monlish, D. A., Greenberg, Z. J., Fisher, D. A. C., Walter, M. J., Oh, S. T., & Schuettpelz, L. G. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.011 · Cited by 12
Sim, H., Park, H. J., Park, G., Kim, Y. J., Park, W., Lee, S., & Choi, M. (2024) · eLife · doi:10.7554/elife.96951 · Cited by 12
Yokomizo‐Nakano, T., Hamashima, A., Kubota, S., Bai, J., Sorin, S., Sun, Y., Kikuchi, K., Iimori, M., Morii, M., Kanai, A., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220962 · Cited by 12
Bahmani, F., Shayanmanesh, M., Safari, M., Alaei, A., Pouriafar, Y., Rasti, Z., Zaker, F., Rostami, S., Damerchiloo, F., & Safa, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03793-z · Cited by 12
Mangaonkar, A. A., & Patnaik, M. M. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2056175 · Cited by 11
Stem Cells in the Myelodysplastic Syndromes
Zhan, D., & Park, C. Y. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.719010 · Cited by 12
Zou, J., Shi, Q., Chen, H., Juskevicius, R., & Zinkel, S. S. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.09.004 · Cited by 10
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression
Matsui, S., Ri, C., Bolanos, L. C., Choi, K., Shibamiya, A., Ishii, A., Takaishi, K., Oshima‐Hasegawa, N., Tsukamoto, S., Takeda, Y., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02245-3 · Cited by 10
Self-citationStoddart, A., Fernald, A. A., Davis, E. M., McNerney, M. E., & Beau, M. M. L. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.08.003 · Cited by 11
Merkerová, M. D., Kléma, J., Kundrát, D., Szikszai, K., Krejčík, Z., Hruštincová, A., Trsová, I., Le, A. V., Čermák, J., Jonasova, A. T., et al. (2022) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20315 · Cited by 10
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
Simoni, Y., & Chapuis, N. (2022) · Diagnostics · doi:10.3390/diagnostics12071659 · Cited by 9
Pellagatti, A., & Boultwood, J. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101055 · Cited by 10
Inflammatory signaling in the pathogenesis of acute myeloid leukemia
Baumann, A., & Ellegast, J. M. (2025) · HemaSphere · doi:10.1002/hem3.70188 · Cited by 9
Muto, T., Walker, C. S., Agarwal, P., Vick, E. J., Sampson, A. M., Choi, K., Niederkorn, M., Ishikawa, C., Hueneman, K. M., Varney, M. E., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282349 · Cited by 9
Self-citationTakashima, K., Olszewska, M., Jethalia, V., Sirenko, M., Silverman, L. R., Tomalin, L. E., Carcamo, S., Hasson, D., & Papapetrou, E. P. (2025) · Blood · doi:10.1182/blood.2024025670 · Cited by 8
Clough, C. A., Cunningham, C., Philbrook, S. Y., Hueneman, K. M., Sampson, A. M., Choi, K., Greis, K. D., & Starczynowski, D. T. (2025) · Leukemia · doi:10.1038/s41375-025-02671-x · Cited by 9
Self-citationChen, L., Bian, Y., Pronk, E., van Dijk, C., van Tienhoven, T. V. D., Hoogenboezem, R. M., Bindels, E. M., Bosch, D. A., Fazeli, S., de Graaf, A. O., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65802-z · Cited by 10
The Mesenchymal Niche in Myelodysplastic Syndromes
Friedrich, C., & Kosmider, O. (2022) · Diagnostics · doi:10.3390/diagnostics12071639 · Cited by 9
Regulation of T-independent B-cell responses by microRNA-146a
King, J. K., Tran, T. M., Paing, M., Yin, Y., Jaiswal, A. K., Tso, C.-H., Roy, K., Casero, D., & Rao, D. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984302 · Cited by 8
Zhang, P., Whipp, E. C., Skuli, S. J., Gharghabi, M., Saygin, C., Sher, S., Carroll, M. P., Pan, X., Eisenmann, E. D., Lai, T.-H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184021 · Cited by 9
Self-citationImmune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis
de Matos, A. G., Magalhães, S. M. M., & Rauh, M. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_608 · Cited by 7
Wang, Y., Lin, C., Yao, C., Hsu, C., Tsai, C., Hou, H., Chou, W., & Tien, H. (2021) · British Journal of Haematology · doi:10.1111/bjh.17837 · Cited by 7
Wei, Y., Kanagal‐Shamanna, R., Zheng, H., Bao, N., Lockyer, P. P., Class, C. A., Darbaniyan, F., Lü, Y., Lin, K., Yang, H., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01605-1 · Cited by 6
Self-citationClonal hematopoiesis: Molecular basis and clinical relevance
Kunimoto, H., & Nakajima, H. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106457 · Cited by 7
Yanir, A. D., Krauss, A. C., Stein, J., Steinberg‐Shemer, O., Gilad, O., Noy‐Lotan, S., Dgany, O., Krasnov, T., Kodman, Y., Feuerstein, T., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29138 · Cited by 6
Extracellular Vesicles in Myeloid Neoplasms
Karantanou, C., Minciacchi, V. R., & Karantanos, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158827 · Cited by 6
Liang, Q., Zhao, J., Zhang, L., Gao, Z., Pan, H., Fang, L., & Shi, J. (2022) · Medicine · doi:10.1097/md.0000000000031427 · Cited by 6
Putnam, C., Kondeti, L., Kesler, M. B. A., & Varney, M. E. (2023) · Biochemistry and Cell Biology · doi:10.1139/bcb-2022-0374 · Cited by 6
Where There’s Smoke, There’s Fire: Inflammation Drives MDS
Datar, G. K., & Goodell, M. A. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.05.007 · Cited by 8
Munteanu, R. A., Gulei, D., Moldovan, C. S., Azzoni, E., Belver, L., Feder, R., Pîrv, S., Buzoianu, A. D., Einsele, H., Mittelman, M., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07861-0 · Cited by 5
TIFAB accelerates MLL-AF9−Induced acute myeloid leukemia through upregulation of HOXA9
Zhao, J., Xiu, Y., Fu, L., Dong, Q., Borcherding, N. C., Wang, Y., Li, Q., Silva, N. S. D., Klein, U., Boyce, B. F., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103425 · Cited by 5
Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding
Kida, J., & Chlon, T. M. (2024) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000854 · Cited by 4
TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells
Lawler, M. E., Romer-Seibert, J. S., Bowman, M. S., Mitra, R., Eischen, C. M., Bowman, R. L., & Meyer, S. E. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017018 · Cited by 4
Park, C. S., Bridges, C. S., Lewis, A. H., Chen, T. J., Shai, S., Du, W., Puppi, M., Zorman, B., Pavel, S., & Lacorazza, H. D. (2025) · Experimental Hematology · doi:10.1016/j.exphem.2025.104730 · Cited by 5
Metadata
- Authors
- Muto, T., Walker, C. S., Choi, K., Hueneman, K., Smith, M. A., Gul, Z., Garcia-Manero, G., Ma, A., Zheng, Y., & Starczynowski, D. T.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- University of Cincinnati (US)
- University of California, San Francisco (US)
- Corresponding author
- Starczynowski, Daniel T.
- ORCID
- Venue
- Nature Immunology
- Published
- 2020-04-20
- Volume
- 21
- Issue
- 5
- Pages
- 535-545
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- PMC
- PMC7402480
- OpenAlex
- W3017327186
- Cited by
- 155
- References
- 59
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 30 · 2023: 24 · 2022: 24 · 2021: 28 · 2020: 16
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R35HL135787)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK102759, R01DK113639)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- myelodysplastic syndrome, hematopoietic stem and progenitor cells, chronic inflammation, non-canonical NF-κB signaling, Toll-like receptor signaling, TRAF6, A20, clonal dominance, myelopoiesis, disease progression, competitive advantage
- MeSH terms
- Tumor Necrosis Factor alpha-Induced Protein 3, Aged, Animals, Cell Differentiation, Cells, Cultured, Hematopoietic Stem Cells, Humans, Inflammation, Male, Mice, Transgenic, Myelodysplastic Syndromes, Signal Transduction, NF-kappa B, Myelopoiesis, TNF Receptor-Associated Factor 6, Toll-Like Receptors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
